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1. Introduction 
Post-transplant lymphoproliferative disorder (PTLD) is a clearly recognized and potentially 
life threatening complication after solid organ or bone marrow transplantation. It comprises 
a spectrum of diseases ranging from infectious mononucleosis and lymphoid hyperplasia to 
highly aggressive lymphoma. The disease has increased clinical importance in view of the 
constantly rising number of organ transplant recipients and the development of more potent 
and specific immunosuppressive drugs. 
PTLD is a relatively common malignancy after transplantation with a reported incidence 
ranging from 2% to 10%. It is the most common form of post-transplant malignancy after 
skin cancer with an overall mortality often exceeding 50%.  
Registry-based reports however usually do not provide details of treatment and outcome: 
the existing single institution studies are largely reports and only a few studies include a 
significant number of patients with PTLD. Most cases of PTLD are associated with Epstein 
Barr virus (EBV) that leads to uncontrolled B cell proliferation in patients with a decreased 
function of EBV specific T cell because of immunosuppressive drugs. PTLD is not 
exclusively associated with EBV infection as EBV-negative PTLD, often developing late after 
transplantation. 
Post transplant lymphomas differ from lymphomas in general population in 
histopathological findings, increased extranodal involvement, a more aggressive clinical 
course and poorer response to conventional treatment.  
Treatment of PTLD consists always in reduction of immunosuppression (RI) as first step. 
The role of chemotherapy (CT) remains unclear. In the past it was reserved for patients in 
whom other treatment options have failed even if the increased toxicities from cytotoxic 
agents, the high susceptibility to life-threatening infections and the necessity to maintain the 
allograft. Actually (Rituximab Hera) most authors consider new anti CD20 monoclonal 
antibodies (mAB) essential for treatment or as single agent or in association with CT but 
there is not a definitive agreement about schedules, duration of treatment and setting of 
patients. 
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2. Pathogenesis 
The appearance of PTLD is often associated with clinical or serological reactivation of 
Epstein Barr virus infection. Tumour tissues often contain EBV-DNA sequences and express 
viral protein (Purtilo DT,1980; Young L et al, 1989; Hanto DW et al, 1981). In normal 
individuals, host defence mechanism make EBV infection a self limited disease and B cell 
proliferation is controlled by specific T cell lymphocytes. The infection is however not 
eradicated, but persists in clinical latent form. In transplanted patients, partial suppression 
of T lymphocyte to prevent graft rejection, makes EBV-driven B cell proliferation uncontrolled 
and predispose to development of PTLD.  
Several single centre studies have found that EBV seronegative patients had a 10-76 times 
greater incidence of PTLD than EBV seropositive recipients (Walker RC et al, 1995). 
Active viral replication in immunosuppressed patients results in the expression of EBV 
encoded genes including oncogenes as LMP1, a gene that inhibits apoptosis by up 
regulating the anti-apoptotic gene BCL-2 (Kulwichit W et al, 1998). 
Data suggests also that prophylactic anti-Cytomegalovirus (CMV) immunoglobulin prevent 
the development of early post-transplant non Hodgkin lymphoma while prophylactic 
treatment with antiviral drugs does not reduce the risk of PTLD (Opelz G et al, 2007). 
Locker and Nalesnick (Locker J & Nalesnick M, 1989) demonstrated that monomorphic 
PTLDs display a strong clonal immunoglobulin rearrangement band on Southern Blotting 
and a c-myc gene rearrangement exhibits disease progression. Also alterations of p53 and N-
ras seem to be implied in pathogenesis of PTLD. BCL 6, that encodes a transcriptional 
repressor gene rearranged in 35-40% of diffuse large B cell lymphoma in immunocompetent 
patients (Bastard C et al, 1994; Lo Coco F et al, 1994), presents frequent somatic mutations in 
PTLD representing probably a consistent step in the progression from a PTLD that can be 
controlled by a reconstituted immune system to one that will require more aggressive 
therapeutic intervention (Cesarman E et al, 1998). 
PTLD also have genomic aberration common to lymphomas in immunocompetent patients 
such as gain of 8q24, 3q2718q21 and loss of 17p13. 
In conclusion viral oncogenes, impaired immune system, chronic antigen stimulation and 
genetic aberration probably contribute together to pathogenesis of PTLD (Poirel HA et al, 
2005).  
3. Risk factors 
The most important risk factor for PTLD development is the intensity of 
immunosuppression administered. Induction and rejection treatment with anti-T cell 
antibodies, especially OKT3 and ATG may lead to an increased risk of PTLD, as 
demonstrated by the higher incidence of early PTLD in hearth and hearth/lung recipient. 
With longer follow-up, is now evident that antibody prophylaxis increased the risk of 
lymphoma primarily during the first post-transplant year, whereas in subsequent years the 
risk is similar to that in non antibody-treated patients. Whether IL2 receptor blocking 
monoclonal antibody, which was introduced in the late 1990s, also increases the risk of 
lymphoma is of great interest. Analysis of the critical 12-months data showed that use of 
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anti IL2 receptor antibodies was not associated with an increased risk of lymphoma (Opelz 
G et al, 2003).  
There is no conclusive evidence that development of PTLD is associated with a single 
immunosuppressive agent (Gao SZ et al, 2003; Pirsch JD et al, 1997; Weisner RH et al, 1998; 
Younes BS et al, 2000). Also the effect of everolimus and sirolimus on PTLD development is 
not clear. These drugs may theoretically be associated with a lower risk as demonstrated in 
animal model but the lack of prospective randomized trial assessing these differences 
restrains any firm conclusion (Yakupoglu YK et al, 2006; Majewski M et al, 2003; Kusuki S et 
al, 2009).  
A special category of patient at risk (10 to 50 fold increased risk) are EBV seronegative 
patients receiving allograft from EBV seropositive donors, leading to primary EBV infection 
(Walker RC et al, 1995). This is also the reason for the higher incidence of early PTLD 
observed in paediatric transplant recipients who often are still EBV seronegative at the time 
of transplantation.  
A high incidence of EBV related lymphoproliferative disorders has been reported in a 
number of congenital immunodeficiency syndromes including severe combined 
immunodeficiency (SCID), ataxia teleangiectasia and Wischott Aldrich syndrome 
Waldmann TA et al, 1983). Acquired immunodeficiency due to HIV disease has become a 
major clinical problem in many parts of the world. An increased incidence of aggressive non 
Hodgkin lymphoma which shares many of the unusual characteristics of PTLD is a 
manifestation of AIDS. The introduction of the Highly Active Antiretroviral Therapy 
(HAART) has dramatically reduced the incidence of this life threatening manifestation of 
HIV. 
The underlying indication for transplantation may also influence the risk for PTLD. For 
example Hepatitis C infection (Burra P et al, 2006) is associated with a particularly high risk 
of PTLD in liver transplant recipients. 
Recent data also suggest Hepatitis B virus reactivation as a possible risk factor for 
development of PTLD( Leblond V & Choquet S, 2004; Duvoux C et al, 2002; Zhang A et al 
2009). 
Also patients with immunological disorders before liver transplantation receiving steroids 
and patient transplanted for autoimmune hepatitis seems to be at higher risk for 
development of PTLD (Zimmermann T et al, 2010; Shpilberg O et al, 1999) 
4. Epidemiology 
The incidence of PTLD after solid organ transplantation is different in children and adults 
and varies according to the type of organ transplanted.  
The incidence is significantly higher in paediatric recipients and has been reported in 1-10% 
of kidney or liver transplants and 6-19 of hearth, lung and hearth and lung transplants. 
However the true incidence of PTLD in adult and paediatric recipients is difficult to 
determine with accuracy(Leblond V & Choquet S, 2004; Patel H et al, 2007).  
PTLD is surprisingly uncommon (<1 %) in the setting of allogenic bone marrow 
transplantation in the absence of specific T-cell manipulation such as use of a monoclonal 
www.intechopen.com
 
Liver Transplantation – Technical Issues and Complications 
 
312 
anti CD3 antibody or T cell depletion of donor marrow. The incidence of PTLD would be 
expected to increase with the duration of immunosuppression and few studies standardise 
their data on incidence for this variable. Also the lack of standardised diagnostic criteria for 
PTLD may reflect the wide range in incidence. 
Although PTLD may occur at any time after transplantation, the risk of developing PTLD is 
greatest within the first year and declines over time thereafter. A report by the Transplant 
Collaborative Study showed the incidence of PTLD to be 224/100000 in the first year, 
54/100000 in the second year and 31/100000 in the sixth year following transplantation11.  
The higher incidence of PTLD in paediatric transplant recipient is attributable in large part 
to the development of primary EBV infection after transplantation. EBV seronegative adults 
who acquire primary EBV infection after transplantation are also at increased risk of PTLD 
but since most adults are already EBV seropositive at the time of transplantation this is a 
less problem. 
In both children and adult, PTLD is more common after hearth and lung transplantation 
than after kidney or liver transplantation. This may be because more intensive 
immunosuppression is used in recipient of thoracic organ. In lung recipient the large 
number of EBV-infected lymphocytes residing in lung transplants in the form of bronchus 
associated lymphoid tissue may be a contributing factor in EBV seronegative recipients. 
5. Pathologic features 
A standardised approach to the classification of PTLD is important to allow consistency of 
reporting and to enable comparison of different treatments. Histology is essential also in 
differentiation between rejection and PTLD involvement of the graft. The classification of 
PTLD currently used is based on the histopathological appearance of the tumour. PTLD can 
be divided into three distinct morphological groups, as reported by the World Health 
Organization classification of neoplastic disease of the haematopoietic and lymphoid tissues.  
The first group comprises diffuse B cell hyperplasia, characterised by differentiated plasma 
cell and preservation of the normal lymphoid architecture. This type of PTLD is most often 
seen in children and young adults, usually occur within the first year following 
transplantation and responds well to reduction of immunosuppression (Kahan BD et al, 
2000). 
The second group comprises polymorphic PTLD characterised by nuclear atypia, tumour 
necrosis and destruction of underlying lymphoid architecture. Lesions in this group are 
highly polymorphic, usually monoclonal and include plasmacytes and blast form. 
Polymorphic PTLD is the most common type of PTLD in both children and adults and may 
occur at any time after transplantation. 
The third group comprises monomorphic PTLD and includes high grade invasive 
lymphoma of B or T lymphocytes. This type of PTLD is often seen several years after 
transplantation and resembles non Hodgkin lymphoma. Monomorphic B cell PTLD can be 
further divided into diffuse large cell lymphoma and Burkitt or Burkitt like lymphoma. 
PTLD may also present with discordant lesions, in which different histological subtypes can 
be present in a single patient. 
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Although the association between EBV and PTLD is well established, the presence of EBV in 
tumour cell is not required for the diagnosis. So, according to the international classification, 
any lymphoma arising in the post-transplant patient is considered to be a PTLD. 
At least 90% of PTLD that occur in solid organ transplant patients arise from recipient cells 
(Weissmann DJ et al, 1995) and the opposite apply in the case of bone marrow 
transplantation. Donor derived PTLD in organ transplant patient may have a predilection 
for the allograft (Strazzabosco M et al, 1996). Some authors have suggested that they may 
have a worse and some a better prognosis than recipient organ PTLD even if further studies 
are needed in this area (Lones MA et al, 1997; Howard TK et al, 1992).  
Clinical recurrence of PTLD has been estimated to occur in approximately 5% of cases. Wu 
et al.30 (Wu TT et al 1996) examined a series of 11 such patients and found that the recurrent 
tumours comprised a heterogeneous assortment. In some cases the recurrence was 
morphologically and clonally identical to the original tumour. In several cases PTLD 
recurred in a more aggressive form. For example, patients with mononucleosis-like PTLD 
could present later with polymorphic PTLD, and patients whose original disease was 
polymorphic PTLD might later develop one of the lymphomatous forms of PTLD. 
6. Clinical presentation  
The clinical presentation of PTLD is highly variable. PTLD may arise at any time after 
transplantation with a significantly higher risk in the first post-transplant year, especially in 
heart and lung recipient because of the high dose of immunosuppression. Most patients 
present with fever (seen in 50%), lymphadenopathy (seen in 30%) or non-specific symptoms 
such as tonsillitis (particularly children) and weight loss. Around 15% of patients present as 
an emergency with intestinal perforation (Kahan BD et al 2000) or with fulminant PTLD 
characterised by disseminated systemic disease that clinically resembles septic shock 
(Orjuela M et al, 2003). Keeping in mind that PTLD often present at extra nodal sites (Bakker 
NA et al, 2005), including the allograft and digestive tract, there may be early signs and 
symptoms that should at least include PTLD in the differential diagnosis. This is especially 
true for allograft involvement of PTLD. The most commonly affected extranodal site of 
PTLD is observed in the gastrointestinal tract (G.I.). There seem to be no relation between 
the time of onset and the development of PTLD in the G.I. tract (Leblond V et al, 1995). The 
CNS is involved in up to 30% of cases of PTLD and in many of these the disease is confined 
to the CNS (Maecker B et al, 2007; Penn I & Porat G, 1995). In this respect, PTLD contrasts 
with NHL in the general population where only around 1% of cases shows isolated CNS 
involvement. Skin involvement is observed in approximately 5-10% of all PTLD patients 
and must be differentiated by other cutaneous malignancy, given the fact that organ 
allograft recipients have an increased risk for the development of cutaneous malignancy 
such as squamous and basal cell carcinoma (Beynet DP et al, 2004). The Canadian PTLD 
Survey Group analysed 90 cases of PTLD occurring in 4283 solid organ transplant recipients 
followed over a nine-year period (Allen U et al, 2001). Approximately two thirds of patients 
presented with disease localised to a single site, of which only a quarter were within the 
lymph nodes. The remaining patients had solitary lesions at extra-nodal sites including 
kidney, bowel, liver, mediastinum and skin. More rarely, solitary lesions were seen in the 
lung, tonsils and central nervous system (CNS). In particular, CNS involvement, especially 
in paediatric patients seems to be a risk factor for poor prognosis (Maecker B et al, 2007). In 
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patients presenting with multiple lesions, the lymph nodes and liver were most commonly 
affected. In PTLD occurring after liver transplantation abdominal findings are the most 
common manifestation including PTLD within liver allograft and splenic abnormalities (Wu 
L et al, 2001). Portal masses have also been reported presenting as lesion with mass effect 
and intrahepatic bile duct dilatation: they have sometimes initially been treated as abscess 
until the diagnosis of PTLD was made (Strouse PJ et al, 1996; Armes JE et al, 1994; Sokal EM 
et al, 1993). Some studies have reported rates of 50% and 30% of PTLD affecting the bowel 
associated with high perforation rate. So after transplantation the presence of 
gastrointestinal disturbance should alert the clinician to the potential diagnosis of PTLD as 
well as the more common complications of infection and inflammation (Starzl TE et al, 1984; 
Steiber AC et al, 1991). Given this myriad of nonspecific clinical signs and symptoms, often 
masquerading PTLD as infection or adverse drug effects or reactions, or even absence of 
symptoms at all, methods for early detection of PTLD in transplant recipients would be 
extremely valuable. 
7. Diagnosis of PTLD 
The diagnosis of PTLD should be based on histological examination of biopsy tissue. 
Excision biopsy is preferable and needle biopsy should only be performed where excision of 
affected tissue in not practicable, also because PTLD may contain large areas of necrosis. 
Cytological preparation are useful, particularly in the analysis of effusion (Lechapt-Zalcman 
E et al, 2001) and can provide adequate diagnostic material particularly if ancillary studies 
such as phenotypic, clonal and viral analysis are also performed. Tissue should be subjected 
to standard histology, examined for the presence of EBV by immunostaining or in-situ 
hybridization, cellular infiltrates characterised by relevant phenotypic markers and clonality 
estimated. Although it would be ideal to sample each tumour in cases of multicenter PTLD, 
this is seldom possible. Each tumour may represent a separate clone and the histological 
grade may be underestimated in multicentric cases. The surgeon run also the risk, in this 
case, of sampling a reactive node that may contain evidence of EBV infection, while the 
primary lymphomatous PTLD lies elsewhere. It is also useful consider biopsy of any lesion 
that respond in an atypical fashion, particularly if regression is documented in other 
concurrent lesion. 
There is no separate staging system for PTLD and it is currently staged using the same 
system as non Hodgkin Lymphoma (NHL) in the normal population. Staging of the disease 
should include computed tomography (CT) of the abdomen and thorax and bone marrow 
aspiration. Fluorodeoxyglucose positron emission tomography (FDG-PET) scanning is 
increasingly used as an important tool in the visualization of malignant lymphoma, 
especially for the detection of extranodal localization and post-treatment evaluation and has 
shown to be superior over conventional diagnostic techniques to differentiate between 
residual masses as a result of vital tumour or scar tissue. Bakker et al. (Bakker NA et al, 
2006) reported a cases of 12 patients whit a highly avid FDG PTLD. Additional sites of 
extranodal localization of PTLD not visualized on CT scanning were found in 50% of all 
patients. (figure 1) 
Additional investigations should be performed as indicated, e.g. CT or magnetic resonance 
scan of the cranium and spinal cord or further gastrointestinal imaging. The presence of 
PTLD within the graft itself may sometimes be mistaken for acute rejection and if there is 
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diagnostic doubt, in-situ hybridisation for EBV encoded RNA, and PCR for VDJ heavy-chain 
rearrangements to determine clonality may be helpful. Molecular analysis of oncogenes and 
tumour suppressor genes will undoubtedly play an increasingly important role in 
predicting behaviour even if, at present, these techniques are not widely available and few 
genes have been analyzed. 
 
Fig. 1. Example of discordant finding. CT abdomen (A) and FDG PET fused with the same 
CT scan (B). Arrow indicates the histologically confirmed focal lesion with high uptake of 
FDG, whereas the CT scan (A) does not show any abnormalities at the site of high FDG 
uptake. The high uptake in the allograft, including the kidney calices and pyelum, is 
physiological, as is the modest uptake in liver and spleen 
8. EBV DNA load monitoring after transplantation 
Because elevation of EBV-DNA load in blood is considered to reflect aberrant EBV induced 
B-cell proliferation, much effort has been put in developing methods that might identify 
patients at risk for developing PTLD by measuring the amount of circulating EBV-DNA in 
the peripheral blood. More recently, pre-emptive strategies to prevent PTLD have been 
evaluated. Mc Diarmid et al. (McDiarmid SV et al, 1998) treated pre-emptively with 
intravenous ganciclovir 18 high-risk (donor positive for EBV serology, recipient negative for 
EBV serology) paediatric liver recipient and no one developed PTLD whereas they 
previously reported 10% incidence of post transplant lymphoproliferative disease (PTLD) in 
paediatric patients receiving first liver grafts and primarily immunosuppressed with 
tacrolimus. Despite the consensus that PTLD patients have a significantly higher EBV-DNA 
load compared with healthy EBV-seropositive donors or non-PTLD transplant recipients, it 
is still unclear which threshold values are predictive for PTLD. Many different threshold 
values have been reported, all with different sensitivity (60–100%) and specificity (71–100%) 
(Lee TC et al, 2005; Rowe DT et al, 2001; Tsai DE et al, 2002). Another limitation of EBV- 
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DNA load monitoring may be the observation that PTLD developing late after 
transplantation is not necessarily associated with EBV (negative staining for EBV in the 
tumour), and may therefore develop without a concomitant rise in EBV-DNA load. Indeed, 
there are studies showing EBV-negative PTLD developing late after transplantation without 
a rise in EBV-DNA load. These observations suggest that, although increased EBV-DNA 
load is generally considered to represent an increase in circulating EBV-positive tumour 
cells, these high EBV-DNA loads in reality may represent a separate population of 
proliferating B-cells that may have nothing to do with development of PTLD. Instead, these 
proliferating B-cells may only reflect a general state of decreased T-cell surveillance in the 
transplant recipient. In conclusion, because of the many variables that may influence the 
immune response of the individual transplant recipient, such as level of 
immunosuppression, time after transplantation, concomitant infections, type of organ 
transplanted, but also genetic factors, an exact cut-off value of EBV-DNA load critical for the 
development of PTLD in the individual patient cannot be defined. Therefore, rising EBV-
DNA loads in the individual patient, instead of using a cut-off value, may be more 
appropriate to identify the individual patient at risk for the development of PTLD. It has 
been suggested that concomitant combined monitoring of EBV-DNA load and EBV-specific 
cytotoxic T lymphocytes (CTL) responses (the absence of which may be used as a marker for 
possible overimmunosuppression) might better identify the individual patient at risk for 
PTLD development. The positive predictive value of high EBV-DNA loads as a predictor for 
PTLD development might be improved with this method. Smets et al.(Smets F et al, 2002) 
showed that high EBV-DNA loads in patients who underwent primary EBV infection were 
indicative for PTLD development only if there was a low concomitant cellular immune 
response.  
9. Clinical management 
The treatment of PTLD poses a major therapeutic challenge and, although there is 
reasonable agreement about the overall principles of treatment no controlled studies have 
been undertaken and most of the recommendations result from small cohorts at single 
institutions.  
Even if no uniform approaches to the treatment have emerged, general principles are largely 
shared. 
• Treatment must be individualised according to clinical situation and the type of organ 
transplanted 
• Unlike non-Hodgkin lymphoma in immunocompetent patients, PTLD can be 
eradicated by surgical resection 
• Reduction of immunosuppression is considered the first line treatment 
• Antiviral agents have showed to induce regression of disease in some cases 
• Chemotherapy, traditionally considered a last resort treatment, is associated with high 
response rate and long progression free survival 
• Rituximab has emerged as treatment of choice especially in early PTLD after failure in 
reduce/withdrawal immunosuppression 
• Radiotherapy may be appropriate for treatment of localized PTLD together with 
reduction in immunosuppression 
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Treatment 
 
Comments 
 
 
Treatments enhancing recipient CTL function 
Reduction of 
immunosuppression 
First line treatment for PTLD 
 More likely to induce remission in early or polymorphic 
PTLD 
Adoptive T cell therapy Risk of graft versus host disease in case of allogenic 
CTLs and need for dedicated facilities. 
Need for growing autologous CTLs 
Cytokine based therapies 
Interferon-alpha Several case reports of successful induction of remission with 
reduction of immunosuppression and interferon-a 
 May significantly increase the risk of organ rejection 
Anti IL-6 antibodies Promising results in phase one to two trials 
Antiviral agent Under development 
Acyclovir, ganciclovir 
Treatments reducing tumour mass 
Surgical excision For localized disease 
 Most cases not amenable to surgical resection 
Local radiation Adjunct to surgical excision 
 Treatment of choice for CNS PTLD 
Chemotherapy Used in aggressive disease 
 High mortality from sepsis and toxicity 
 Effective in around 2/3 of selected patients 
Rituximab Promising results when combined with reduction in 
immunosuppression 
 Longer term results required to determine relapse rates 
Table 1. Treatment of PTLD 
9.1 Reduction of immunosuppression 
Reduction of immunosuppression is the initial treatment in all patients with PTLD with the 
aim of increase antitumor activity. In EBV driven PTLD, this may partially restores CTL 
function resulting in an increase of EBV specific CTLs and elimination of virally infected 
lymphocytes, including those which constitute the tumour. The approach to reduce 
immunosuppressive drugs needs to be carefully individualised and will depend on the 
nature and extent of disease, the type of transplant recipient (life or no-life supporting graft) 
and the time from transplantation. 
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In general most clinicians adjust the corticosteroid dose to 10 mg of Prednisone daily in the 
hope to prevent allograft rejection. Steroids also are an important component of most 
chemotherapy regimen for PTLD and lymphoma in general. 
A response to reduction in immunosuppression is usually seen within 2-4 weeks (Green M 
et al, 1999). 
Reduction in immunosuppression leads to long term disease remission in 40-86% of 
paediatric patients and 25-63% of adults. 
If PTLD develops within one year of the transplant up to 80% will respond to reducing in 
immunosuppression. 
In contrast, after one year the response rate falls to 10% with 80% of mortality (Armitage JM 
et al, 1991). 
9.2 The role of rituximab 
PTLD is usually of B cell origin and the use of mAB to deplete B cell is a logical approach for 
treatment. Rituximab, a monoclonal antibody directed against CD20 antigen expressed on 
mature and immature B cells, results in profound and long-lasting depletion of B cell (6-8 
months), together with hypogammaglobulinemia.  
Rituximab is widely used in the treatment of diffuse large B cell lymphoma in 
immunocompetent patients with an overall survival at two years of 70% compared with 
57% of patients treated with chemotherapy alone (Coiffier B et al, 2002). 
Many more case reports and case series of using rituximab in PTLD are described in 
literature. This cases included paediatric and adult PTLD patients who underwent solid 
organ or bone marrow transplantations and achieved excellent results with rituximab. Most 
of the patients also underwent concurrent RI and some received also antiviral therapy. 
Many patients experienced clinical improvement within a few days after the first infusion. 
Most patients were treated with the standard dose of rituximab at 375 mg/m2 once a week 
for four consecutive weeks. The majority of the case reports describe the use of rituximab in 
the early onset PTLD, but it might be effective also for patients with late onset PTLD. 
Gonzalez-Barca et al (Gonzalez-Barca E et al, 2004) reviewed data on 108 adult solid organ 
transplanted patients with PTLD including 36 patients who received rituximab. With a 
mean follow-up of 15 months, the OS of patients treated with rituximab was significantly 
better than for the whole group (76% vs. 21). In a multicenter, prospective phase II study, 
Oertel et al.(Oertel SH et al, 2005) treated 17 adult patients with PTLD with standard dose of 
rituximab. The mean follow-up time was 24 months. Overall response rate was obtained in 
12 (71%) patients. Nine patients (53%) achieved complete remission (CR), with a mean 
duration of 17.8 months. Two patients relapsed, respectively 3 and 5 months after obtaining 
CR. The mean overall survival was 37 months with 11 (65%) patients alive at the end of the 
study. Adverse events were rare and of low grade. Patients whose tumour was EBV positive 
were significantly more likely to achieve CR than patients with tumors that were EBV 
negative. The largest prospective trial of using rituximab in PTLD was published by 
Choquet et al.(Choquet S et al, 2005). This multicenter, open label, European phase II trial, 
enrolled 63 patients with PTLD after solid organ transplantation who did not improve after 
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reduction of immunosuppression. The study included both paediatric and adult patients 
who were treated with standard dose of Rituximab 375 mg/m2 weekly for 4 weeks. Most of 
the PTLD cases were of relatively late onset with only 17 patients with PTLD diagnosed 
<1 year after their transplantation. The overall response rate after single agent rituximab 
was 59% with a CR rate of 42% and a partial response rate of 17%. Stable disease was 
observed in 3% of patients and 38% progressed during treatment. At a median follow up of 
16,3 months, median progression free survival was 6.0 months. Trappe et al. (Trappe RU et 
al, 2007) reported the efficacy of single agent Rituximab in eight patients (seven adults, one 
paediatric) with PTLD relapsed or refractory to chemotherapy after failure of reduction in 
immunosuppression. Complete remission was obtained in three patients and partial 
remission in two. Patient achieving CR either remain in CR or were successfully salvaged 
again with single agent Rituximab. In conclusion patients treated with rituximab benefit 
from the short duration of such therapy in terms of response rate and less toxic effect. 
However, because of the high relapse rate observed in several studies, the combination of 
Rituximab with cytotoxic drugs is recommended to be evaluated.  
9.3 Antiviral agents 
Because most PTLDs arise as a consequence of EBV infection, prophylactic measures should 
include avoiding over-immunosuppression of the recipient such as the use of anti-
lymphocyte preparations, antiviral agents, EBV vaccination, in-vitro generated EBV specific 
CTL lines and avoiding, in EBV seronegative recipients, transplantation with an organ from 
an EBV positive donor. Regression has been described following high dose acyclovir. 
Targeting EBV by antiviral agents has been attempted also for prophylaxis of PTLD. An 
alternative approach, especially in high risk recipients, is to prospectively monitor the EBV 
viral load after transplantation and to initiate therapy when a pre-determined threshold is 
exceeded. One problem with this approach is that only a minority of patients with high EBV 
loads develops PTLD, and some patients with EBV-positive PTLD may have a low serum 
viral load  
9.4 Cytokine based therapy 
Agents that alter the cytokine environment of the tumour to favour remission, notably 
interferon-α (Davis CL et al, 1998) and anti-IL-6 have been tried as adjuvant along with 
reduction of immunosuppression, but at present there is insufficient evidence to 
recommend their routine use. Interferon-α enhances T-lymphocyte cytotoxicity and has 
been used as an adjunct to chemotherapy to treat B cell malignancies in non-transplanted 
patients and in the maintenance of remission in such patients. Swinnen et al. (Swinnen LJ et 
al, 2008) recently reported results of a trial for treatment of PTLD starting with a defined 
course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to 
chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant 
recipients. Reduction in immunosuppression produced no CR, progressive disease and 
rejection were frequent; response to IFN was rare while chemotherapy resulted in 57% 
durable CR. IL-6 may play a role in the development of PTLD by promoting the growth of 
EBV-infected B cells and increasing tumour development in EBV-immortalised cells. Serum 
levels of IL-6 are raised in the majority of patients with PTLD. Anti-IL-6 mAb has been used 
in a phase 1–2 multi-centre clinical trial in 12 patients with PTLD that was refractory to a 
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reduction of immunosuppression (Haddad E et al, 2001). Five of the 12 patients showed a 
complete response with no residual tumour and three patients showed a decrease in tumour 
size, which in one case was sufficient to allow surgical removal of a previously unresectable 
tumour. Anti-IL-6, therefore, appears to be a promising adjunct in the treatment of PTLD 
but further studies are needed to fully assess its efficacy. 
9.5 Rapamycine 
Rapamycine is increasingly used as an immunosuppressive agent for solid organ 
transplantation. In addition to its immunosuppressive effects, it also displays anti-
angiogenic and anti-tumour properties, and this make it a potentially attractive agent for 
patients in remission from PTLD, particularly those who develop chronic allograft rejection 
as a consequence of a reduction of immunosuppression. Rapamycin inhibits the growth of 
EBV-transformed B lymphocyte lines in-vitro by arresting cell cycle in the G1 phase 
(Vaysberg M et al, 2007). There are no prospective studies addressing the use of rapamycin 
in the treatment or prevention of PTLD. 
9.6 Adoptive T cell therapy 
Adoptive T cell therapy using EBV-specific CTL lines has generated considerable interest as 
a treatment for PTLD. Adoptive immunotherapy was initially advocated in allogenic bone 
marrow transplantation to control PTLD that was donor cell in origin. Donor CTL would 
restore immune surveillance against EBV driven proliferation and control PTLD. A potential 
risk was graft versus host disease due to the donor cell infusion: this risk could be reduced 
by selecting donor EBV-specific T cell ex vivo prior to infusion. This approach has been used 
with success as prophylaxis and treatment of PTLD after stem cell transplantation using 
CTL lines derived from the donor and specific for EBV gene products even if it is limited by 
the time required to generate the CTLs (weeks to months) and the expense for dedicated 
facilities. Haque et al (Haque T et al, 2007) presented the results of a recent multicenter 
clinical trial using Epstein-Barr virus-specific CTL generated from EBV-seropositive blood 
donors to treat patients with EBV-positive PTLD on the basis of the best HLA match and 
specific in vitro cytotoxicity. The response rate (complete or partial) in 33 patients was 64% 
at 5 weeks and 52% at 6 months. Fourteen patients achieved a complete remission, 3 showed 
a partial response, and 16 had no response at 6 months (5 died before completing treatment). 
No adverse effects of CTL infusions were observed. These results showed that allogeneic 
CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for 
individual patients. After solid organ transplantation, PTLD is usually of recipient origin 
and recipient derived CTLs are required for effective killing of EBV infected B cells. It is 
possible to generate autologous EBV-specific CTLs from recipients who were EBV 
seropositive prior to transplantation. However, this approach is not applicable when PTLD 
arises in recipients who were EBV seronegative prior to transplantation. Savoldo et al 
(Savoldo B et al, 2006) treated 12 patients with persisting high EBV-DNA viral load with no 
evidence of PTLD (6 patients) or high EBV-DNA load with previous or current clinical 
diagnosis of PTLD (6 patients). Ten of the 12 patients had no evidence of overt PTLD 
following CTLs therapy, despite being categorized at high risk because of persisting of high 
EBV-DNA viral load. The two remaining patients both had evidence of pre-existing PTLD 
and both appeared to respond to CTLs infusion. 
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9.7 Chemotherapy 
Conventional cytotoxic chemotherapy which has been shown to be curative for many 
lymphomas in non-PTLD setting, has been viewed as a treatment of last resort due to very 
high morbidity and mortality rates. Chemotherapy is commonly used in the treatment of 
PTLD when reduction in immunosuppression fails to control the disease. 
Various multi-drug regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone) have been used in PTLD patients (Wasson S et al, 2006; Elstrom RL et al, 
2006; Trappe R et al, 2007; Taylor AL et al, 2006; Fohrer C et al, 2006; Buadi F et al, 2007; 
Patel H et al, 2007; Aversa SML et al, 2008) 
In spite of the high response rate up to 70%, the associated toxicity is significant and 
includes treatment-related deaths in about 25% of patients. The high mortality of the 
standard chemotherapy regimens in the PTLD population might occur because of various 
factors including baseline pharmacologic immunosuppression, graft dysfunction, and 
colonization with resistant or hospital acquired infectious organisms. 
Sepsis and other complication of chemotherapy have been the major problem in some 
centres, while others have found refractory disease to be common.  
PTLDs after liver transplantation reported in literature are most of all cases report and only 
few studies analyze a larger group of this disease. (Table 2) 
Ben-Ari et al ( Ben-Ari Z et al, 1999) reported a series of 7 patients who developed PTLD 
between 1988 and 1997. 2 patients with late PTLD received anthracycline based 
chemotherapy and actually they are alive with no recurrence of disease respectively 10 
months and 24 months after the end of treatment. Another one with polyclonal tumour EBV 
positive, was initially treated with high dose acyclovir IV. However he progressed to 
monoclonalty and systemic chemotherapy (CHOP) was instituted: the patient died 7 months 
later after one cycle of chemotherapy of septicaemia and rapidly progressive lymphoma. 
Norin et al (Norin S et al, 2004) observed, in a population of 500 consecutive recipients of 
liver graft, 9 cases of monomorphic PTLD, one case of polymorphic PTLD and two case of 
unclassifiable NHL developed at a median time from transplantation of 19,5 months (1,5-
148). Chemotherapy (CHOP or VACOP-B) was used in all patients mostly upfront but in 
one patient 4 months after diagnosis because of lack of response to reduced 
immunosuppression alone. Ten patients had a complete remission, one a partial remission 
and one a stable disease. Six patients are alive and in complete remission more than 4 years 
after the lymphoma diagnosis while 6 patients died because of progression of lymphoma in 
three, neutropenic sepsis in two and recurrence of cirrhosis in one. 
Lorenzini et al (Lorenzini S et al, 2006) described a small series of 4 monomorphic PTLD. 
Two were early PTLD and EBV was detected in tumour tissue. The other was late PTLD and 
only one presented Latent membrane protein type 1 in lymphoma tissue. In all patients the 
immunosuppressive regimen was reduced. All patients underwent also two consecutive 
cycles of Rituximab and no severe adverse events were observed during the treatment 
period. Two patients received chemotherapy at progression but they died despite CHOP 
therapy. Only one patient, with monomorphic late PTLD is alive 5 years after disease onset. 
In this case lymphoma remission was obtained with reduction in immunosuppression and 
Rituximab administration. 
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 Number of 
patients who 
received 
chemotherapy/ 
Chemotherapy response Therapy 
related 
mortality 
*Ben Ari et al  
(102) 
4/7 2 CHOP  
1 Vincristine  
1 MACOP-B  
2 CR 
2 PD 
None 
*Norin et al. 
(103) 
12/12 8 CHOP  
1 Epi CEBOP  
1 Paclitaxel  
1 VACOP B  
1 BFM90 course  
10 CR 
1 SD 
1 PD 
2 neutropenic 
sepsis 
*Lorenzini et 
al. (104) 
4/4 2 R+CHOP  
2 Rituximab 
1 CR 
3 PD 
None 
*Kremers et 
al. (105) 
11/37 11 CHOP or 
BACOP 
5 Rituximab 
na None 
*Avolio et al. 
(106) 
 
5/5  1 R+CVP 
1 R+CHOP 
2 CHOP 
1 ABVD 
3 CR 
2 PD 
None 
*Patel et al. 
(107) 
10/17 5 CHOP 
5 Rituximab 
8 CR 
2 PD 
None  
* retrospective study 
CR: complete remission; PD: progression disease; SD: stable disease; CHOP-R cyclophosphamide, 
doxorubicin, vincristine, prednisone, rituximab; MACOP B: Methotrexate, doxorubicin, 
cyclophosphamide, vincristine, prednisone, bleomycin; CEBOP: cyclophosphamide, etoposide, 
bleomycin, vincristine, prednisone; VACOP-B: etoposide, doxorubicin, cyclophosphamide, vincristine, 
prednisone, bleomycin; BACOP: bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone; 
CVP: cyclophosphamide, vincristine, prednisone ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine. 
Table 2. Chemotherapy treatment of patients with PTLD after liver transplantation 
In a retrospective study by Kremers et al (Kremers WK et al, 2006), among 1206 liver 
transplantation recipients, 37 patients developed PTLD. Eleven received chemotherapy 
(CHOP-BACOP) because of stable or progressive disease despite reduction of 
immunosuppression. Surprisingly, survival post PTLD diagnosis was very similar both for 
the EBV positive and EBV negative PTLD regardless of treatment received. 
Avolio et al (Avolio AW et al, 2007) treated 5 patients with PTLD after liver transplantation. 
Two patients with early EBV positive PTLD received three doses of R-CVP and CHOP 
respectively but, after an initial response, they relapsed with progression of lymphoma and 
rapidly died. Among the three cases of late PTLD, 2 presented a monomorphic monoclonal 
disease and one a Hodgkin Lymphoma. EBV was negative in one. They received soon 
discontinuance of immunosuppression and chemotherapy (R-CHOP-ABVD) and they are 
alive without evidence of disease. 
In a retrospective analysis of 17 consecutive cases (6 early and 11 late disease) of PTLD 
associated with liver transplantation (Patel H et al, 2007), 5 patients received chemotherapy 
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(CHOP), 4 obtained CR and one developed progression of disease. At a median follow up of 
4,25 years only 5 patients of the entire series are alive and in clinical and radiological 
remission. 
Marino et al (Marino D et al, 2010) reported on 10 consecutive cases of PTLD after liver 
transplantation with seven monomorphic diseases. Chemotherapy was used in eight 
patients. No treatment-related mortality was observed and no patient developed graft 
rejection during chemotherapy. At a median follow-up period of 25 months, 6 of the 10 
patients were alive and without evidence of disease. 
10. Conclusion 
The patients with PTLD can be treated with chemotherapy with an overall response rate of 
77% obtaining a long term disease free survival. 
In immunocompetent patients, Rituximab administration represents an important step in 
the treatment of non Hodgkin Lymphoma and currently immunochemotherapy is the gold 
standard for this kind of patients (Coiffier B et al, 2002; Pfreundschuh M et al, 2008). 
However, Rituximab increases the risk of CMV and Aspergillus infections (Hirokawa M et 
al, 2007; Askoy S et al, 2007; Suzan F et al, 2001; Van der Velden WJ et al, 2006) both in 
immunocompetent and in post transplant immunosuppressed patients. Recent data also 
report an anti-rejection activity of Rituximab (Kaposztas Z et al, 2009; Mulley WR et al 2009).  
In conclusion Rituximab represents a good option in the treatment of PTLD but there are 
few studies with small population, so the survival rate with the use of this antibody needs to 
be assessed together with chemotherapy administration in patients with PTLD. 
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